Parkinson Disease Treated With a Suspected Dopamine Receptor Agonist

摘要: A single-blind crossover trial of a putative dopamine receptor stimulating agent, piribedil, was conducted in 16 patients with idiopathic parkinsonism. At maximum dose levels overall improvement parkinsonian signs averaged 30%. Adverse effects included gastrointestinal disturbances, behavioral alterations, and dyskinesias, but were severe enough to require drug withdrawal only one patient. The antiparkinsonian efficacy levodopa together peripheral decarboxylase inhibitor, tested 12 these patients, about twice that piribedil. Levodopa treatment failures due toxic other than dyskinesias responded well As expected agonist, piribedil substantially reduced the central turnover this monoamine as estimated by probenecid loading test.